Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.4
(-5.2%)
USD 0.4
(-5.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 172.86 Million USD | 70.78% |
| 2022 | 100.89 Million USD | 15.46% |
| 2021 | 87.38 Million USD | -56.49% |
| 2020 | 200.85 Million USD | 35.02% |
| 2019 | 148.75 Million USD | -9.29% |
| 2018 | 163.99 Million USD | -26.46% |
| 2017 | 223.01 Million USD | 0.82% |
| 2016 | 221.19 Million USD | 85.84% |
| 2015 | 119.02 Million USD | 9.51% |
| 2014 | 108.69 Million USD | 1.77% |
| 2013 | 106.8 Million USD | 7.21% |
| 2012 | 99.61 Million USD | -14.08% |
| 2011 | 115.94 Million USD | 15.22% |
| 2010 | 100.62 Million USD | -0.03% |
| 2009 | 100.65 Million USD | -21.88% |
| 2008 | 128.85 Million USD | 3.03% |
| 2007 | 125.07 Million USD | -2.31% |
| 2006 | 128.02 Million USD | 14.52% |
| 2005 | 111.79 Million USD | 2.39% |
| 2004 | 109.19 Million USD | 3.57% |
| 2003 | 105.43 Million USD | 7.48% |
| 2002 | 98.09 Million USD | -71.91% |
| 2001 | 349.21 Million USD | 564.46% |
| 2000 | 52.55 Million USD | 169.52% |
| 1999 | 19.5 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 46.28 Million USD | -1.98% |
| 2024 Q2 | 56.69 Million USD | 22.79% |
| 2023 FY | 172.31 Million USD | 70.78% |
| 2023 Q3 | 49.78 Million USD | 11.76% |
| 2023 Q2 | 44.54 Million USD | 42.94% |
| 2023 Q1 | 31.16 Million USD | 2.84% |
| 2023 Q4 | 47.22 Million USD | -5.15% |
| 2022 Q3 | 23.13 Million USD | -3.78% |
| 2022 FY | 100.89 Million USD | 15.46% |
| 2022 Q1 | 23.41 Million USD | -7.6% |
| 2022 Q2 | 24.04 Million USD | 2.67% |
| 2022 Q4 | 30.3 Million USD | 31.0% |
| 2021 Q2 | 18.19 Million USD | -12.81% |
| 2021 FY | 87.38 Million USD | -56.49% |
| 2021 Q1 | 20.86 Million USD | 181.06% |
| 2021 Q3 | 22.98 Million USD | 26.34% |
| 2021 Q4 | 25.34 Million USD | 10.26% |
| 2020 FY | 200.85 Million USD | 35.02% |
| 2020 Q4 | 7.42 Million USD | -85.76% |
| 2020 Q1 | 69.86 Million USD | 26.64% |
| 2020 Q2 | 71.41 Million USD | 2.21% |
| 2020 Q3 | 52.14 Million USD | -26.98% |
| 2019 Q3 | 40.55 Million USD | 50.77% |
| 2019 Q1 | 26.13 Million USD | -9.48% |
| 2019 Q2 | 26.9 Million USD | 2.94% |
| 2019 Q4 | 55.17 Million USD | 36.03% |
| 2019 FY | 148.75 Million USD | -9.29% |
| 2018 Q3 | 29.34 Million USD | -32.29% |
| 2018 Q1 | 62.64 Million USD | -1.03% |
| 2018 FY | 163.99 Million USD | -26.46% |
| 2018 Q2 | 43.34 Million USD | -30.8% |
| 2018 Q4 | 28.86 Million USD | -1.63% |
| 2017 FY | 223.01 Million USD | 0.82% |
| 2017 Q4 | 63.29 Million USD | 13.31% |
| 2017 Q3 | 55.86 Million USD | 23.02% |
| 2017 Q2 | 45.4 Million USD | -22.31% |
| 2017 Q1 | 58.45 Million USD | 7.51% |
| 2016 Q4 | 54.36 Million USD | -16.1% |
| 2016 Q3 | 64.79 Million USD | 14.42% |
| 2016 Q1 | 45.4 Million USD | 23.07% |
| 2016 FY | 221.19 Million USD | 85.84% |
| 2016 Q2 | 56.63 Million USD | 24.74% |
| 2015 Q1 | 26.56 Million USD | 10.6% |
| 2015 Q4 | 36.89 Million USD | 29.48% |
| 2015 Q3 | 28.49 Million USD | 5.22% |
| 2015 Q2 | 27.07 Million USD | 1.92% |
| 2015 FY | 119.02 Million USD | 9.51% |
| 2014 FY | 108.69 Million USD | 1.77% |
| 2014 Q4 | 24.01 Million USD | -16.38% |
| 2014 Q3 | 28.72 Million USD | 9.06% |
| 2014 Q2 | 26.33 Million USD | -11.04% |
| 2014 Q1 | 29.6 Million USD | 25.06% |
| 2013 FY | 106.8 Million USD | 7.21% |
| 2013 Q2 | 28.36 Million USD | 15.05% |
| 2013 Q1 | 24.65 Million USD | -1.04% |
| 2013 Q3 | 30.11 Million USD | 6.19% |
| 2013 Q4 | 23.67 Million USD | -21.39% |
| 2012 Q4 | 24.91 Million USD | -15.36% |
| 2012 FY | 99.61 Million USD | -14.08% |
| 2012 Q2 | 25.67 Million USD | -13.49% |
| 2012 Q3 | 29.43 Million USD | 14.62% |
| 2012 Q1 | 29.68 Million USD | -11.88% |
| 2011 Q4 | 33.68 Million USD | 29.33% |
| 2011 Q1 | 29.73 Million USD | 25.57% |
| 2011 Q2 | 26.48 Million USD | -10.93% |
| 2011 Q3 | 26.04 Million USD | -1.64% |
| 2011 FY | 115.94 Million USD | 15.22% |
| 2010 Q3 | 25.03 Million USD | -1.08% |
| 2010 FY | 100.62 Million USD | -0.03% |
| 2010 Q2 | 25.3 Million USD | -4.89% |
| 2010 Q1 | 26.6 Million USD | 14.39% |
| 2010 Q4 | 23.67 Million USD | -5.42% |
| 2009 Q3 | 23.88 Million USD | -7.31% |
| 2009 FY | 100.65 Million USD | -21.88% |
| 2009 Q2 | 25.77 Million USD | -7.09% |
| 2009 Q1 | 27.73 Million USD | 1.83% |
| 2009 Q4 | 23.25 Million USD | -2.63% |
| 2008 Q1 | 33.33 Million USD | 3.27% |
| 2008 Q3 | 32.33 Million USD | -10.06% |
| 2008 Q2 | 35.95 Million USD | 7.86% |
| 2008 FY | 128.85 Million USD | 3.03% |
| 2008 Q4 | 27.23 Million USD | -15.76% |
| 2007 FY | 125.07 Million USD | -2.31% |
| 2007 Q2 | 30.59 Million USD | -6.11% |
| 2007 Q3 | 29.6 Million USD | -3.23% |
| 2007 Q4 | 32.27 Million USD | 9.0% |
| 2007 Q1 | 32.59 Million USD | 6.37% |
| 2006 Q4 | 30.63 Million USD | -5.2% |
| 2006 Q1 | 31.97 Million USD | 13.5% |
| 2006 FY | 128.02 Million USD | 14.52% |
| 2006 Q2 | 33.09 Million USD | 3.51% |
| 2006 Q3 | 32.31 Million USD | -2.35% |
| 2005 FY | 111.79 Million USD | 2.39% |
| 2005 Q1 | 27.19 Million USD | -1.01% |
| 2005 Q2 | 28.41 Million USD | 4.51% |
| 2005 Q3 | 28.01 Million USD | -1.4% |
| 2005 Q4 | 28.17 Million USD | 0.55% |
| 2004 Q1 | 27.44 Million USD | 5.39% |
| 2004 FY | 109.19 Million USD | 3.57% |
| 2004 Q3 | 27.05 Million USD | -0.6% |
| 2004 Q4 | 27.46 Million USD | 1.52% |
| 2004 Q2 | 27.22 Million USD | -0.81% |
| 2003 FY | 105.43 Million USD | 7.48% |
| 2003 Q3 | 26.97 Million USD | 0.77% |
| 2003 Q4 | 26.04 Million USD | -3.48% |
| 2003 Q1 | 25.63 Million USD | 3.78% |
| 2003 Q2 | 26.77 Million USD | 4.43% |
| 2002 FY | 98.09 Million USD | -71.91% |
| 2002 Q4 | 24.7 Million USD | -3.13% |
| 2002 Q3 | 25.5 Million USD | 1.81% |
| 2002 Q2 | 25.05 Million USD | 9.71% |
| 2002 Q1 | 22.83 Million USD | -92.34% |
| 2001 Q1 | 14.13 Million USD | 485.95% |
| 2001 FY | 349.21 Million USD | 564.46% |
| 2001 Q4 | 297.89 Million USD | 1288.95% |
| 2001 Q3 | 21.44 Million USD | 36.27% |
| 2001 Q2 | 15.73 Million USD | 11.36% |
| 2000 Q4 | -3.66 Million USD | -125.69% |
| 2000 Q1 | 29.23 Million USD | 0.0% |
| 2000 FY | 52.55 Million USD | 169.52% |
| 2000 Q3 | 14.25 Million USD | 12.02% |
| 2000 Q2 | 12.72 Million USD | -56.47% |
| 1999 FY | 19.5 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | 37.192% |
| Alkermes plc | 996.24 Million USD | 82.648% |
| Agenus Inc. | 78.18 Million USD | -121.108% |
| Aptorum Group Limited | 10.56 Thousand USD | -1635987.45% |
| Ardelyx, Inc. | 169.93 Million USD | -1.725% |
| Dyadic International, Inc. | 9.15 Million USD | -1788.722% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -676.835% |
| Lantern Pharma Inc. | 17.87 Million USD | -866.96% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -2467.891% |
| Novavax, Inc. | 779.12 Million USD | 77.812% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -113.255% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -110.313% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -790.228% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -483.899% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -225.392% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 54.567% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -611.202% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -356.492% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -461.792% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -104.057% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -890.256% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -2.632% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -428.409% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -8.187% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 90.396% |
| AlloVir, Inc. | 180.93 Million USD | 4.457% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 61.217% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -482.403% |
| Bicycle Therapeutics plc | 216.92 Million USD | 20.308% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -0.563% |
| ChromaDex Corporation | 56.37 Million USD | -206.619% |
| Chimerix, Inc. | 93.38 Million USD | -85.106% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1142.8% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -14.836% |
| CRISPR Therapeutics AG | 463.49 Million USD | 62.703% |
| Precision BioSciences, Inc. | 92.46 Million USD | -86.96% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 31.953% |
| Fortress Biotech, Inc. | 200.19 Million USD | 13.65% |
| Fortress Biotech, Inc. | 200.19 Million USD | 13.65% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -427.909% |
| ImmuCell Corporation | 9.61 Million USD | -1697.468% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -9.54% |
| Immix Biopharma, Inc. | 16.14 Million USD | -970.986% |
| Incyte Corporation | 1.19 Billion USD | 85.479% |
| Innoviva, Inc. | 132.15 Million USD | -30.809% |
| IO Biotech, Inc. | 91.44 Million USD | -89.046% |
| Jaguar Health, Inc. | 42.01 Million USD | -311.446% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -2.122% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -105.008% |
| ContextLogic Inc. | 387 Million USD | 55.331% |
| MiMedx Group, Inc. | 229.72 Million USD | 24.75% |
| MEI Pharma, Inc. | 34.78 Million USD | -396.964% |
| NextCure, Inc. | 67.63 Million USD | -155.583% |
| Onconetix, Inc. | 34.9 Million USD | -395.221% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1256.261% |
| Opthea Limited | 191.96 Million USD | 9.949% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -6182.524% |
| Vaxcyte, Inc. | 468.04 Million USD | 63.065% |
| PDS Biotechnology Corporation | 43.04 Million USD | -301.598% |
| Precigen, Inc. | 84.18 Million USD | -105.354% |
| Pharming Group N.V. | 225.49 Million USD | 23.337% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -3.004% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -138.223% |
| PureTech Health plc | 144.59 Million USD | -19.552% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -32.708% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 29.487% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -611.202% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 24.406% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -460.19% |
| Acelyrin, Inc. | 422.06 Million USD | 59.042% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1340593.346% |
| Summit Therapeutics Inc. | 87.68 Million USD | -97.145% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -366.407% |
| Senti Biosciences, Inc. | 94.7 Million USD | -82.534% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -39.915% |
| Elevation Oncology, Inc. | 45.44 Million USD | -280.392% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -486.613% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -4285.259% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -30.788% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -407.17% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -1945.545% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 4.651% |
| Seer, Inc. | 110.49 Million USD | -56.457% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -144.878% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -84.93% |
| ESSA Pharma Inc. | 32.13 Million USD | -437.961% |
| GlycoMimetics, Inc. | 39.28 Million USD | -340.035% |
| GT Biopharma, Inc. | 13.57 Million USD | -1173.343% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 21.362% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 14.045% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 33.365% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -204.567% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -219.654% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -1639.537% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 57.164% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -813.25% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -241.012% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 33.425% |
| Aptose Biosciences Inc. | 52.35 Million USD | -230.18% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1099.615% |
| Soligenix, Inc. | 7.79 Million USD | -2117.619% |
| Century Therapeutics, Inc. | 56.07 Million USD | -208.304% |
| Kura Oncology, Inc. | 165.8 Million USD | -4.261% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -50.968% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -1978.002% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -6865.921% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -60.513% |
| Autolus Therapeutics plc | 196.72 Million USD | 12.127% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -104.199% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -48.445% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -791.859% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 46.274% |
| GRI Bio, Inc. | 11.33 Million USD | -1425.763% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2350.061% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -31.767% |
| IGM Biosciences, Inc. | 265.59 Million USD | 34.912% |
| INmune Bio, Inc. | 29.89 Million USD | -478.235% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -0.183% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -328.803% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -981.827% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -998.17% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -178.381% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -60.775% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 37.297% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 42.654% |
| Verastem, Inc. | 92.08 Million USD | -87.73% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -863.649% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 6.922% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -42.388% |
| Histogen Inc. | 14.27 Million USD | -1111.246% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -977.19% |
| Surrozen, Inc. | 18.55 Million USD | -831.908% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1059.028% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3296.09% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -189.693% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -574.032% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -267.759% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2164.805% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 2.957% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -256.814% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 29.442% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1024.968% |
| Apollomics, Inc. | 54.14 Million USD | -219.3% |
| Amarin Corporation plc | 272.35 Million USD | 36.529% |
| Mesoblast Limited | 5.9 Million USD | -2828.99% |
| Turnstone Biologics Corp. | 78.33 Million USD | -120.671% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 29.187% |
| Synaptogenix, Inc. | 8.31 Million USD | -1979.288% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1085.171% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 31.687% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -418.658% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -1857.473% |
| Exelixis, Inc. | 1.58 Billion USD | 89.106% |
| Better Therapeutics, Inc. | 38.26 Million USD | -351.803% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 25.504% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 79.786% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1364.115% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2049.602% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -476.364% |
| Gritstone bio, Inc. | 148.37 Million USD | -16.509% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -151.041% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -956.642% |
| Avid Bioservices, Inc. | 25.99 Million USD | -564.983% |
| Insmed Incorporated | 949.26 Million USD | 81.789% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1001.793% |
| MediWound Ltd. | 18.86 Million USD | -816.202% |
| OmniAb, Inc. | 83.89 Million USD | -106.054% |
| Alector, Inc. | 248.8 Million USD | 30.519% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 26.221% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -230.843% |
| Zai Lab Limited | 547.47 Million USD | 68.424% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 56.637% |
| Aura Biosciences, Inc. | 84.99 Million USD | -103.397% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 30.052% |
| Immunic, Inc. | 99.22 Million USD | -74.223% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -8.714% |
| Veracyte, Inc. | 357.93 Million USD | 51.704% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 98.083% |
| FibroGen, Inc. | 398.11 Million USD | 56.578% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1116.531% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -2409.732% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2325.982% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 94.69% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -568.144% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 45.388% |
| TG Therapeutics, Inc. | 198.47 Million USD | 12.901% |
| Galecto, Inc. | 35.62 Million USD | -385.219% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -324.854% |
| Fortrea Holdings Inc. | 457.3 Million USD | 62.198% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -218.488% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -498.618% |
| XBiotech Inc. | 37.51 Million USD | -360.861% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -151.041% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -737.179% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -21.686% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -74.483% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -56.137% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 81.96% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -499.303% |
| Vaxxinity, Inc. | 56.05 Million USD | -208.414% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 59.858% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -674.908% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -55.925% |
| NexImmune, Inc. | 28.16 Million USD | -513.718% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3025.486% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -866.153% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.86% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -579.009% |
| Scopus BioPharma Inc. | 11.71 Million USD | -1375.636% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -36.051% |
| Ainos, Inc. | 12.95 Million USD | -1234.621% |
| Pluri Inc. | 22.48 Million USD | -668.99% |
| Prothena Corporation plc | 282.4 Million USD | 38.787% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 13.575% |
| Celularity Inc. | 215.05 Million USD | 19.617% |
| Rallybio Corporation | 78.93 Million USD | -119.01% |
| Cue Biopharma, Inc. | 19.54 Million USD | -784.602% |
| MeiraGTx Holdings plc | 151.07 Million USD | -14.424% |
| Omeros Corporation | 94.75 Million USD | -82.446% |
| Humacyte, Inc. | 23.49 Million USD | -635.707% |
| Immunocore Holdings plc | 308.04 Million USD | 43.881% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -4999.381% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -99.009% |
| Blueprint Medicines Corporation | 722.86 Million USD | 76.085% |
| CalciMedica, Inc. | 21.81 Million USD | -692.359% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -131.542% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -7.68% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -0.919% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 41.388% |
| Pulmatrix, Inc. | 22.03 Million USD | -684.413% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -399.983% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -94.528% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 68.659% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -138.272% |
| Cytokinetics, Incorporated | 173.61 Million USD | 0.428% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -402.249% |
| Nutriband Inc. | 5.73 Million USD | -2914.79% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -296.37% |
| Vor Biopharma Inc. | 126.03 Million USD | -37.158% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 85.463% |
| Evogene Ltd. | 27.79 Million USD | -522.055% |
| ProKidney Corp. | 151.52 Million USD | -14.088% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -133.056% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2147.316% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 71.856% |
| CorMedix Inc. | 48.95 Million USD | -253.098% |
| BioLineRx Ltd. | 50.8 Million USD | -240.28% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -14.711% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -354.058% |
| Atai Life Sciences N.V. | 125.78 Million USD | -37.432% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -111.747% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -112.346% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 31.551% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -428.005% |
| MediciNova, Inc. | 10.9 Million USD | -1485.916% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -34.194% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2281.272% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2770.542% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 63.71% |
| Biomea Fusion, Inc. | 126.13 Million USD | -37.051% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 86.822% |
| Mereo BioPharma Group plc | 35.84 Million USD | -382.308% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 9.535% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 24.825% |
| Absci Corporation | 73.66 Million USD | -134.666% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -526.746% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -29.403% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 28.614% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 34.032% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 16.888% |
| Allakos Inc. | 196.05 Million USD | 11.827% |
| Imunon, Inc. | 20.31 Million USD | -751.134% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -52.349% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 53.103% |
| BioAtla, Inc. | 129.68 Million USD | -33.297% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1364.115% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -991.138% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -103.572% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -313.978% |
| XOMA Corporation | 46.46 Million USD | -272.057% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -55.498% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -21.343% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1231.913% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -66.772% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 0.001% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 32.145% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -362.118% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2001.798% |
| Akari Therapeutics, Plc | 16.8 Million USD | -928.615% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -7502.079% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 42.246% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2469.118% |
| UroGen Pharma Ltd. | 138.88 Million USD | -24.466% |
| Sutro Biopharma, Inc. | 243 Million USD | 28.863% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -2276.33% |
| Orgenesis Inc. | 45.75 Million USD | -277.798% |
| Entera Bio Ltd. | 8.86 Million USD | -1851.117% |
| GH Research PLC | 41.22 Million USD | -319.361% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -572.433% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -108.143% |
| Xencor, Inc. | 306.97 Million USD | 43.687% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -3403.908% |
| Replimune Group, Inc. | 234.77 Million USD | 26.368% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -743.68% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 9.868% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -2469.118% |
| Portage Biotech Inc. | 18.19 Million USD | -849.882% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2281.272% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -64.698% |
| OncoCyte Corporation | 25.63 Million USD | -574.295% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -2735.96% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1408.842% |
| Purple Biotech Ltd. | -22.46 Million USD | 869.435% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -948.962% |
| scPharmaceuticals Inc. | 65.17 Million USD | -165.226% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -1945.125% |
| HilleVax, Inc. | 133.34 Million USD | -29.64% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -1580.788% |
| Tharimmune, Inc. | 9.45 Million USD | -1728.292% |
| Genprex, Inc. | 31.06 Million USD | -456.555% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 7.816% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -450.942% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -22497.255% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3073.702% |
| OKYO Pharma Limited | 8243.57 USD | -2096916.22% |
| Savara Inc. | 15.74 Million USD | -997.93% |
| Curis, Inc. | 58.35 Million USD | -196.237% |
| Daré Bioscience, Inc. | 33.6 Million USD | -414.347% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -3294.588% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2216.968% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -539.734% |
| BeiGene, Ltd. | 3.28 Billion USD | 94.74% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -766.976% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 65.341% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -12.507% |
| Erasca, Inc. | 141.52 Million USD | -22.147% |
| bluebird bio, Inc. | 240.23 Million USD | 28.041% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3718.644% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 90.101% |
| DBV Technologies S.A. | 92.16 Million USD | -87.575% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -3718.644% |
| Moderna, Inc. | 6.39 Billion USD | 97.296% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -305.71% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1103.32% |
| Molecular Templates, Inc. | 63.09 Million USD | -173.999% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -159.17% |
| Travere Therapeutics, Inc. | 472 Million USD | 63.375% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -20.625% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -178.453% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -298.187% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 16.942% |
| MacroGenics, Inc. | 217.21 Million USD | 20.416% |
| RenovoRx, Inc. | 11.39 Million USD | -1416.927% |
| Adicet Bio, Inc. | 152.03 Million USD | -13.701% |
| Prime Medicine, Inc. | 186.63 Million USD | 7.378% |
| Aditxt, Inc. | 25.95 Million USD | -566.142% |
| Adagene Inc. | 41.83 Million USD | -313.252% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2264.797% |
| Quantum-Si incorporated | 111.65 Million USD | -54.819% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -0.593% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1085.84% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -382.578% |
| SciSparc Ltd. | 9.01 Million USD | -1818.422% |
| Vericel Corporation | 142.04 Million USD | -21.704% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1896.947% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -648.72% |
| Generation Bio Co. | 144.46 Million USD | -19.66% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -108.201% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -99.941% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 41.543% |
| Invivyd, Inc. | 205.75 Million USD | 15.983% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -139.567% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -1743.247% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -129.714% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -1580.461% |
| 2seventy bio, Inc. | 289.88 Million USD | 40.367% |
| ADMA Biologics, Inc. | 66.58 Million USD | -159.618% |
| Clene Inc. | 41.07 Million USD | -320.882% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1249.708% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -215.477% |
| GeoVax Labs, Inc. | 6.02 Million USD | -2770.542% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 50.896% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -370.622% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -412.539% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -66.698% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -430.452% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -1.522% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 77.483% |
| Evaxion Biotech A/S | 22.27 Million USD | -676.242% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -27.537% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 26.402% |
| Trevena, Inc. | 38.41 Million USD | -350.027% |
| Surrozen, Inc. | 18.55 Million USD | -831.908% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -116.235% |
| Cingulate Inc. | 22.75 Million USD | -659.557% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2407.381% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -287.017% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -1999.469% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -68.557% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 77.076% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -178.489% |
| Clearmind Medicine Inc. | 8.74 Million USD | -1877.601% |
| Kronos Bio, Inc. | 128.11 Million USD | -34.93% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -105.62% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5793.961% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -71.451% |
| Statera Biopharma, Inc. | 28.82 Million USD | -499.625% |
| ImmunityBio, Inc. | 362.87 Million USD | 52.361% |
| Korro Bio, Inc. | 84.53 Million USD | -104.496% |
| Kineta, Inc. | 21.15 Million USD | -717.116% |
| BioVie Inc. | 31.95 Million USD | -441.058% |
| Codexis, Inc. | 66.51 Million USD | -159.883% |
| Celularity Inc. | 215.05 Million USD | 19.617% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 23.719% |
| Celcuity Inc. | 66.23 Million USD | -161.012% |
| Virax Biolabs Group Limited | 6.54 Million USD | -2540.405% |
| Cibus, Inc. | 320.3 Million USD | 46.03% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -302.021% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -410.782% |
| IN8bio, Inc. | 30.33 Million USD | -469.829% |
| Kodiak Sciences Inc. | 277.32 Million USD | 37.665% |
| Annexon, Inc. | 143.72 Million USD | -20.279% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -35.487% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -654.59% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -26910.781% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 77.826% |
| Eyenovia, Inc. | 25.4 Million USD | -580.414% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -23.201% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3008.037% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -118.454% |
| Arcellx, Inc. | 200.19 Million USD | 13.651% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -276.621% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 20.12% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -1636.155% |
| Moolec Science SA | 52.75 Million USD | -227.71% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -182.752% |
| Geron Corporation | 70.44 Million USD | -145.41% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -271.442% |
| Royalty Pharma plc | 862.4 Million USD | 79.955% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -83.762% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -1753.253% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -663.943% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 16.815% |
| Humacyte, Inc. | 23.49 Million USD | -635.707% |
| Structure Therapeutics Inc. | 102.77 Million USD | -68.201% |
| 89bio, Inc. | 151.2 Million USD | -14.328% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -115.73% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1088.92% |
| Genelux Corporation | 24.33 Million USD | -610.372% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -409.592% |
| Notable Labs, Ltd. | 14.77 Million USD | -1070.406% |
| Liquidia Corporation | 87.98 Million USD | -96.478% |
| Mustang Bio, Inc. | 48.5 Million USD | -256.424% |
| Immunovant, Inc. | 282.7 Million USD | 38.853% |
| Quantum-Si incorporated | 111.65 Million USD | -54.819% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -666.807% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -712.851% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -69.459% |
| Acasti Pharma Inc. | 11.3 Million USD | -1429.679% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -654.191% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -981.827% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -271.426% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -15136.387% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -988.185% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -492.89% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -317.719% |
| PepGen Inc. | 84.76 Million USD | -103.937% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -483.406% |
| United Therapeutics Corporation | 885.1 Million USD | 80.469% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -654.985% |
| Solid Biosciences Inc. | 104.31 Million USD | -65.718% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -428.239% |
| Immuneering Corporation | 58.41 Million USD | -195.943% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -3296.09% |
| Silo Pharma, Inc. | 3.92 Million USD | -4307.836% |
| Belite Bio, Inc | 31.66 Million USD | -445.879% |
| XOMA Corporation | 46.46 Million USD | -272.057% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -155.913% |
| Bionomics Limited | 17.89 Billion USD | 99.034% |
| Apogee Therapeutics, Inc. | 93 Million USD | -85.875% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 584.498% |
| uniQure N.V. | 285.08 Million USD | 39.363% |
| Cassava Sciences, Inc. | 105.95 Million USD | -63.15% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2264.797% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 10.987% |
| Forte Biosciences, Inc. | 32.47 Million USD | -432.281% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -1980.564% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -488.09% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3008.037% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1116.531% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -1844.752% |
| Altimmune, Inc. | 30.55 Million USD | -465.745% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 59.577% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 584.498% |
| Compugen Ltd. | 43.97 Million USD | -293.143% |
| Peak Bio, Inc. | 1249.13 USD | -13839052.05% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -133.229% |
| Benitec Biopharma Inc. | 22.38 Million USD | -672.357% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 28.916% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -505.644% |
| Zura Bio Limited | 62.63 Million USD | -175.981% |
| PolyPid Ltd. | 21.04 Million USD | -721.426% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -962.11% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -505.644% |
| Instil Bio, Inc. | 85.78 Million USD | -101.514% |
| argenx SE | 1.53 Billion USD | 88.727% |
| Immunome, Inc. | 122.82 Million USD | -40.75% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -256.629% |
| Verona Pharma plc | 67.15 Million USD | -157.432% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -567.835% |
| Shattuck Labs, Inc. | 93.61 Million USD | -84.661% |
| CervoMed Inc. | 14.95 Million USD | -1055.714% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -144.5% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -1923.279% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -238.959% |
| Moolec Science SA | 52.75 Million USD | -227.71% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -950.975% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -30.413% |
| AnaptysBio, Inc. | 181.56 Million USD | 4.791% |
| Design Therapeutics, Inc. | 78.19 Million USD | -121.088% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -98.606% |
| NeurAxis, Inc. | 8.82 Million USD | -1859.7% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1273.611% |
| Lumos Pharma, Inc. | 38.66 Million USD | -347.094% |
| Achilles Therapeutics plc | 75.25 Million USD | -129.711% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -567.835% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1182.649% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -552.276% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -5793.961% |
| Nutriband Inc. | 5.73 Million USD | -2914.79% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -56.047% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -210.619% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -239.765% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -161.53% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -219.4% |
| Palisade Bio, Inc. | 13.32 Million USD | -1197.815% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -280.693% |
| Beam Therapeutics Inc. | 554.19 Million USD | 68.807% |
| Neurogene Inc. | 55.58 Million USD | -211.011% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 30.432% |
| AEON Biopharma, Inc. | 48.42 Million USD | -256.953% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -78.75% |
| Sesen Bio, Inc. | 78.38 Million USD | -120.55% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -106.957% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1273.405% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 61.669% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -96.688% |
| Athira Pharma, Inc. | 125.46 Million USD | -37.782% |
| Vaccinex, Inc. | 23.45 Million USD | -637.024% |
| HCW Biologics Inc. | 21.02 Million USD | -722.108% |
| XOMA Corporation | 46.46 Million USD | -272.057% |
| Nektar Therapeutics | 190.9 Million USD | 9.447% |
| Arvinas, Inc. | 480 Million USD | 63.986% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -7502.079% |
| Merus N.V. | 200.49 Million USD | 13.778% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -67.258% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -399.333% |
| Rezolute, Inc. | 70.38 Million USD | -145.598% |
| Clene Inc. | 41.07 Million USD | -320.882% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -955.465% |
| BeyondSpring Inc. | 24.86 Million USD | -595.23% |
| Synlogic, Inc. | 58.53 Million USD | -195.341% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -866.18% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -3748.375% |
| Peak Bio, Inc. | 1249.13 USD | -13839052.05% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -185.989% |
| Krystal Biotech, Inc. | 160.42 Million USD | -7.756% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 36.124% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 50.33% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -7915.314% |
| MannKind Corporation | 125.59 Million USD | -37.638% |
| Ikena Oncology, Inc. | 84.57 Million USD | -104.392% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -1691.946% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -92.932% |
| Gossamer Bio, Inc. | 183.75 Million USD | 5.926% |
| CohBar, Inc. | 12.38 Million USD | -1295.422% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -240.803% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -526.746% |
| Legend Biotech Corporation | 583.14 Million USD | 70.356% |
| Mural Oncology plc | 192.07 Million USD | 9.997% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -157.449% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -970.71% |
| Disc Medicine, Inc. | 91.12 Million USD | -89.705% |
| Champions Oncology, Inc. | 28.11 Million USD | -514.973% |
| REGENXBIO Inc. | 321.15 Million USD | 46.173% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3124.426% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -210.046% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -343.702% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -51.166% |
| Vaxart, Inc. | 90.72 Million USD | -90.54% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -1928.977% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -303.955% |
| Cellectis S.A. | 97.32 Million USD | -77.629% |
| Longeveron Inc. | 21.25 Million USD | -713.501% |
| Repare Therapeutics Inc. | 167.35 Million USD | -3.294% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 87.297% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -128.527% |
| Revolution Medicines, Inc. | 498.76 Million USD | 65.341% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -2498.752% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -293.295% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -131.759% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -148.25% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1463.011% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.38% |
| Denali Therapeutics Inc. | 527.23 Million USD | 67.212% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -1896.947% |
| Veru Inc. | 101.34 Million USD | -70.569% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -638.535% |
| Cingulate Inc. | 22.75 Million USD | -659.557% |
| Passage Bio, Inc. | 108.38 Million USD | -59.489% |
| Context Therapeutics Inc. | 25.07 Million USD | -589.473% |
| Exicure, Inc. | 14.07 Million USD | -1128.112% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 16.109% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -299.226% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -1783.661% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 31.532% |
| Nuvalent, Inc. | 149.49 Million USD | -15.638% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2042.942% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -66.781% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -705.954% |
| OmniAb, Inc. | 83.89 Million USD | -106.054% |
| Anew Medical, Inc. | 1.3 Million USD | -13189.018% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -427.619% |
| Lipocine Inc. | 15.08 Million USD | -1046.336% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -152.316% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -127.005% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -328.803% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -50.526% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -672.288% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 73.971% |
| Ocugen, Inc. | 71.56 Million USD | -141.548% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -84.166% |
| Q32 Bio Inc. | 92.68 Million USD | -86.522% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -716.421% |
| Alumis Inc. Common Stock | 158.17 Million USD | -9.29% |
| Equillium, Inc. | 50.6 Million USD | -241.598% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -177.007% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1143.165% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -816.342% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -268.19% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -59.376% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -1294.923% |
| Dominari Holdings Inc. | 23.83 Million USD | -625.274% |
| Edesa Biotech, Inc. | 9.22 Million USD | -1774.374% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1351.827% |
| Bio-Techne Corporation | 563.03 Million USD | 69.297% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 57.714% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 35.678% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -30.687% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1099.563% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -5.604% |
| Nkarta, Inc. | 131.65 Million USD | -31.31% |
| BioCardia, Inc. | 12.12 Million USD | -1326.194% |
| Iterum Therapeutics plc | 47.46 Million USD | -264.18% |